

Ratti M¹, Procopio G², Guadalupi V², Grizzi G¹, Bonomi M¹, Saleri J¹, Gobbi A¹, Marchi R¹, Pogliacomì G¹, Donati G¹, Nazzari M¹, Bacciocchini N¹, Curti A¹, Brighenti M¹, Perrucci B¹, Giganti M¹, Panni S¹, Donini M¹, Gregorc V³, Passalacqua R¹

1) Medical Oncology, ASST Cremona 2) Medical Oncology, National Cancer Institute, Milan 3) Medical Oncology, San Raffaele Hospital, Milan

Background

- During COVID pandemic, many cancer patients (pts) refused to come to hospital, suspending therapies, with ominous consequences;
- Based on positive results of **DOMONCOVID**, our homecare project for COVID+ cancer pts, we created a model of assistance, **ONCOHOME**, delivering **cancer care at home** to immune-compromised pts;
- We aim to provide data on **feasibility, efficacy and costs of this innovative model**.

Material and Methods

- **ONCOHOME** is a multicenter project involving 3 Cancer Center (CC) of the North of Italy: **National Cancer Institute, San Raffaele in Milan and Cremona CC**;
- We created an **organizational homecare model based on a medical and nursing team** with a car equipped for home visits and a secretariat managing patient calls, with a dedicated phone number;
- The team administers **cancer care at home** and provides pts with the same assistance usually delivered in hospital;
- Patient-reported outcome (**PRO**) **assessment is performed**.

Results

- From August 3rd 2020 to May 5th 2021, **79 cancer pts** were assisted at home by Cremona team;
- All types of cancer were included

Tab 1 Baseline characteristics

Variable	N (%)
Median Age (range)	73 (27-91)
Sex	
Male	41 (57)
Female	32 (43)
Cancer stage	
Methastatic	56 (77)
Non methastatic	17 (23)
Performance status	
0-1	63 (87)
>1	10 (13)
Types of therapy	
chemotherapy	38 (52)
TKIs	23 (32)
Hormonal	11 (15)
Other	1 (1)
Administration	
Oral	57 (78)
Subcutaneous	9 (13)
Intravenous	7 (9)
Patients required hospitalization	
clinical complication	11 (16)
severe toxicity	2 (3)

Figure 1. Types of therapy





Figure 2. Administration routes



Conclusions

- **ONCOHOME** showed that **inpatient or outpatient cancer drug administration** could be successfully **replaced by home administration**, for appropriate therapies and selected pts;
- This model **is feasible at an affordable cost**;
- The project is ongoing, planning to accrue other 100 pts for each center;
- **ONCOHOME** will be **implemented with electronic devices** for PRO evaluation, **certified telemedicine service and non-invasive wearable smart tissue monitoring physiological parameters devices**.

Disclosures

We'd like to thank Dr. Passalacqua who designed ONCOHOME and all the patients and the staff involved in the project

Correspondence: mratti.cremona@gmail.com